News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

QTL Biosystems, LLC Receives $3 Million Award For Development Of Handheld Field Detector For Anthrax, Ricin, And Other Biotoxins

10/19/2005 5:11:49 PM

SANTA FE, N.M., Oct. 12 /PRNewswire/ -- QTL Biosystems, LLC, a provider of innovative solutions for bio-detection, drug discovery, and life science research, announced today that it has received a $3 million award from the U.S. Army through the Joint Science and Technology Office for development of an advanced handheld biodetection system and rapid test cartridges. The QTL Biosensor will include tests for pathogens including Anthrax bacteria, toxins such as ricin, botulinum, Staphylococal Enterotoxin B, and other threat agents. The system is simple, robust, and reliable, and designed for civilian and military first responders, hospital triage personnel, and Haz Mat personnel.

QTL technology will provide improved field-detection performance over currently available systems, in sensitivity, low false positives and negatives, simplicity, and ease of use. The system will set new standards for toxin detection sensitivity. The QTL Biosensor will be developed and tested in conjunction with the U.S. Army Edgewood Chemical Biological Command to validate its performance specifications. The contract includes funding for a Cooperative R&D Agreement with Edgewood personnel. The contract will also support the development of tests for multiple bioterrorism pathogens in one cartridge. This will simplify the task of running multiple tests in the field while lowering costs for consumables.

"QTL has demonstrated an innovative technical approach that leads to a simple cartridge format, excellent sensitivity combined with extremely low false positives," notes Dr. Duncan McBranch, Co-founder and Chief Operating Officer for QTL. "The QTL Biosensor will provide a reliable and simple "YES" or "NO" answer to a field responder in less than five minutes."


QTL Biosystems, LLC of Santa Fe, New Mexico, develops and markets bioassays that deliver superior sensitivity, specificity, and speed in simple to use formats with low total cost of detection. The Company delivers enzyme activity and protein binding assays for the pharmaceutical and life sciences markets, and Biosensor Systems for first responders, medical triage personnel and military users. Bioassay products are available for the detection of viruses, toxins, bacteria, proteins, hormones, nucleic acids and other biological compounds. The Company's novel technologies integrate its expertise in chemistry, molecular and cell biology and instrumentation.

CONTACT: Paul Gindlesperger QTL Biosystems, LLC (505) 424-1000, ext. 116 2778 Agua Fria Street Santa Fe, NM 87507

This release was issued through eReleases(TM). For more information, visit

QTL Biosystems, LLC

CONTACT: Paul Gindlesperger, QTL Biosystems, +1-505-424-1000, ext. 116,

Read at

comments powered by Disqus